Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

By M. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. Gerstein, L. Køber, Francesca C. Lawson, Lin Ping, Xiaodan Wei, E. Lewis and 6 more. New England Journal of Medicine, 2015

2,125 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/43d48dff3394d1326ff494176f0699930adb8c43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Meier
2. M. Nauck
3. G. Bakris
4. R. Eckel
5. John B. Buse
6. V. Basevi
7. D. J. Drucker

Citations in the corpus

• Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis (2016, background): “Agents such as DPP-4 inhibitors (146–148) and GLP-1 receptor agonists (149) have been shown to be safe in this population.”
• Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018, background): “Lixisenatide, a short-acting GLP-1 receptor agonist, did not demonstrate CVD benefit or harm in a trial of patients recruited within 180 days of an acute coronary syndrome admission (50).”